Obesity in acute alcoholic hepatitis increases morbidity and mortality by Parker, Richard et al.
 
 
Obesity in acute alcoholic hepatitis increases
morbidity and mortality
Parker, Richard; Kim, S J; Im, G Y; Nahas, J; Dhesi, B; Vergis, N; Sinha, A; Ghezzi, A; Rink,
M R; McCune, A; Aithal, G P; Newsome, P N; Weston, C J; Holt, A; Gao, B
DOI:
10.1016/j.ebiom.2019.03.046
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Parker, R, Kim, SJ, Im, GY, Nahas, J, Dhesi, B, Vergis, N, Sinha, A, Ghezzi, A, Rink, MR, McCune, A, Aithal,
GP, Newsome, PN, Weston, CJ, Holt, A & Gao, B 2019, 'Obesity in acute alcoholic hepatitis increases morbidity
and mortality', EBioMedicine, vol. 45, pp. 511-518. https://doi.org/10.1016/j.ebiom.2019.03.046
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 17/09/2019
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 23. Oct. 2019
EBioMedicine 45 (2019) 511–518
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comObesity in acute alcoholic hepatitis increases morbidity and mortalityRichard Parker a,b,c,⁎,1, S.J. Kim c,1, G.Y. Im d, J. Nahas d, B. Dhesi a, N. Vergis e, A. Sinha f, A. Ghezzi g, M.R. Rink b,
A. McCune f, G.P. Aithal g, P.N. Newsome a,b, C.J. Weston b, A. Holt a, B. Gao c
a Liver and Hepatobiliary Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
b Centre for Liver Research, University of Birmingham, Birmingham, UK
c National Institute for Alcoholism and Alcohol Abuse, National Institutes of Health, Rockville, MD, USA
d Mount Sinai Medical Centre, New York, NY, USA
e Imperial College Healthcare NHS Foundation Trust, UK
f Department of Liver Medicine, University Hospitals Bristol NHS Foundation Trust, UK
g NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University Of Nottingham, Nottingham, UK⁎ Corresponding author at: Leeds Liver Unit, St Jam
Hospitals Trust, Beckett Street, Leeds LS9 7TF, UK
E-mail address: richardparker@nhs.net (R. Parker).
1 RP and SJK contributed equally to this work and share
https://doi.org/10.1016/j.ebiom.2019.03.046
2352-3964/© 2019 Published by Elsevier B.V. This is an opa b s t r a c ta r t i c l e i n f oArticle history:
Received 12 February 2019
Received in revised form 15 March 2019
Accepted 18 March 2019
Available online 3 July 2019Background: Alcohol and obesity synergise to increase the risk of liver-relatedmortality. We examined the inﬂu-
ence of adiposity on clinical outcomes in alcoholic hepatitis (AH) and the underlying inﬂammatory crosstalk be-
tween adipose tissue (AT) and the liver.
Methods: A cohort of 233 patients with AH from the UK and USA provided data to analyse the effects of obesity in
AH. Bodymass indexwas corrected for the severity of ascites, termed cBMI. Inﬂammatory andmetabolic proﬁling
was undertaken by proteome analysis of human serum samples. The effect of alcohol on adipose tissue and
CXCL11 expressionwas studied in 3 T3-derived adipocytes and inmice using thehigh-fat diet-plus-binge ethanol
model.
Findings: Obesity was common amongst patients with AH, seen in 19% of individuals. Obesity (HR 2.22, 95%CI
1.1–4.3, p= .022) and underweight (HR 2.38, 1.00–5.6, p= .049)were independently associatedwithmortality
at 3 months. Proteome analysis demonstrated multiple metabolic and inﬂammatory factors differentially
expressed in obese AH verse lean AH, with CXCL11 being the most elevated factor in obese AH. In vitro analysis
of cultured adipocytes and in vivo analysis of mouse models showed that alcohol induced CXCL11 expression in
AT, but not in liver.
Interpretation:Obesity is common in AH and associatedwith a greater than two-fold increase in short-termmor-
tality. Obese AH is associated with a different inﬂammatory phenotype, with the greatest elevation in CXCL11.
These data conﬁrm that adiposity is clinically important in acute alcohol-related liver disease and illustrate the
adipose-liver inﬂammatory axis in AH.
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Obesity1. Introduction
Alcoholic liver disease (ALD) is a common form of liver disease
throughout the world and causes a signiﬁcant burden on healthcare re-
sources [1,2]. ALD is a spectrumof disease ranging from simple steatosis
to cirrhosis and hepatocellular carcinoma [3]. Alcoholic hepatitis (AH) ises's Hospital, Leeds Teaching
joint ﬁrst authorship.
en access article under the CC BY-NCan acute form of ALD typiﬁed by jaundice and liver failure [4]. AH has a
high short-term mortality, which has not improved over time despite
trials of multiple agents [5].
The presence of obesity increases the risk of clinically signiﬁcant
liver disease and death in hazardous drinkers [6–8] and increases the
likelihood of AH on liver biopsy [6]. The synergy between alcohol and
obesity is due to hepatic factors and extra-hepatic factors, predomi-
nantly in adipose tissue [9]. For example, ﬂux of fatty acids fromadipose
tissue caused by obesity or alcohol contributes to hepatic steatosis and
inﬂammation [10], and expression of inﬂammatory cytokines in adipose
tissue mirrors the severity of hepatic inﬂammation in AH [11].-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
There is increasing recognition that the combination of alcohol and
obesity is particularly dangerous with regard to liver health. Epide-
miological data have demonstrated an increased risk of cirrhosis or
liver–related deaths in individuals who are both obese and hazard-
ous drinkers. However the effect of obesity in particular types of
alcohol related liver disease have not been described, nor the
mechanisms that cause this synergistic effect.
Added value of this study
This study examined the effect of bodymass in alcoholic hepatitis,
the most florid manifestation of ArLDwith a poor short-term mor-
tality. We found that obesity is associated with increased morbid-
ity and mortality in alcoholic hepatitis. Analysis of serum showed
differing inflammatory profiles in obese/AH suggesting differing
pathological profiles. In vitro studie confirmed that this is due at
least in part to the effect of alcohol on adipose tissue rather than
the liver per se. These data add to the epidemiological data by
reporting on patient-level, rather than population level, effect of
obesity and start to describe mechanisms for this effect.
Implications of all the available evidence
This provides a starting point for further investigations into the
combined effects of obesity and alcohol on liver function and un-
derpins considerations for suggesting lower safe limits of alcohol
when obesity is also present.
512 R. Parker et al. / EBioMedicine 45 (2019) 511–518Understanding the relationship between obesity and ALD is impor-
tant in the face of growing prevalence of obesity [12]. However, there
are very few clinical data on the impact of obesity onmortality andmor-
bidity in AH and mechanistic data are lacking. In this present study we
examined the prevalence and clinical consequences of obesity in pa-
tients with AH and sought to phenotype the inﬂammatory pathways
in AH and obesity.
2. Methods
2.1. Patients
This study used data regarding patients with AH identiﬁed frompro-
spectively maintained departmental databases at University Hospitals
Birmingham NHS Foundation Trust, Birmingham UK, UniversityTable 1
Baseline characteristics of patients included in the study.
All n= 233 Underweight n= 25
Mean Variance Mean Variance
Age years 49.0 53.0 47.0 37.0
Ascites severity⁎ 1.4 1.1 2.0 1.0
Prothrombin time seconds 26.0 8.8 24.7 4.5
Bilirubin Mmol/L 238 162 234 129
Creatinine mmol/L 91.3 70.8 63.0 41.5
Sodium mmol/L 130.9 8.2 123 7.6
Urea mmol/L 8.6 13.4 4.6 5.1
Albumin g/L 24.2 11.3 26.0 7.1
White cell count x106/L 12.5 13.7 13.0 7.9
⁎ Compared by Fisher's exact test.Hospitals Bristol NHS Foundation Trust, Bristol, UK, St Mary's Hospital,
Imperial College NHS Foundation Trust, London UK, Nottingham Uni-
versity Hospitals NHS Trust, Nottingham, UK and Mount Sinai Medical
Centre, New York, NY, USA. Standard deﬁnitions of AH were used to
identify or exclude patients: alcohol use of at least 60 g/d in men and
N 40 g/d in women for N5 years, hazardous drinking until at least six
weeks before admission, abrupt increase in serum bilirubin, elevated
transaminases N50 and b 400 IU/L, aspartate transaminase (AST) to ala-
nine transaminase (ALT) ratio N 2:1, and exclusion of other causes of
liver disease [13]. Importantly, all patients had undergone ultrasound
(US) imaging of the abdomen early in their admission to hospital.
Liver biopsywas performed only in cases of diagnostic uncertainty, con-
sistent with recent NIAAA guidance for trialists [13]. AH was managed
according to local protocols and specialist guidelines [3,14].
Baseline clinical and biochemical characteristics, speciﬁc treatments
for AH and presence of complications during admission (infection or
AKI) were collected. The diagnosis of infection was according to criteria
published by Bajaj [15]. Renal failure was diagnosed in accordance to a
recent expert consensus statement [16]. Follow-upwas to threemonths
after admission. Only observational data were collected, no procedures,
tests or interventions were performed outside of standard care. Blood
samples frompatients with AHwere collectedwithin 48 h of admission,
after obtainingwritten conﬁrmation of informed consent. The collection
of samples was approved by research ethics committee (reference 06/
Q27108/11).2.2. Analysis of body composition and correction for ascites
Body mass index was adjusted for the presence of ascites by
subtracting the weight of ascites from measured body weight, and a
corrected BMI (cBMI) was calculated. Patients were categorised as
underweight (cBMI) b18.5 kg/m2), normal (cBMI 18–5-24.9 kg/m2),
overweight (cBMI 25–29.9 kg/m2) or obese (cBMI ≥30 kg/m2). This is
described in detail in the supplementary information.2.3. Inﬂammatory phenotyping
Blood sampleswere separated into serumby centrifuging and frozen
to−80 °Cwithin an hour of collection, and stored until analysis. Inﬂam-
matory andmetabolic proﬁling (see supplementary table 1 for complete
list) was undertaken by proteome analysis of serum samples (proteome
proﬁler, R&D Systems, USA). This system usesmultiple antibody dots on
a ﬁlm to semi-quantitatively detectmultiple proteins in serum. The size
of the resultingdotwhen theﬁlm is developed corresponds to the abun-
dance of the protein in serum. Enzyme-linked immunosorbant assay
(ELISA) was performed to conﬁrm the results of the proteomic analysis
using Quantikine ELISA kit (R&D Systems, USA). All assays were per-
formed according to the manufacturer's instructions.Normal n= 95 Overweight n= 67 Obese n= 45 p ANOVA
Mean Variance Mean Variance Mean Variance
50.0 49.0 49.0 38.0 50.0 45.0 0.469
1.5 1.1 1.2 1.1 1.1 1.0 0.017
25.6 8.8 26.2 9.3 27.2 9.2 0.700
239 151 236 177 242 177 0.998
89.8 68.3 83.4 49.6 112.6 96.7 0.059
132 7.9 131 8.3 132 8.1 0.002
6.5 8.1 7.7 9.7 15.4 22.7 0.001
24.8 11.4 23.9 11.6 22.6 11.9 0.665
12.4 7.8 11.1 5.5 14.1 26.2 0.716
Fig. 1. distribution of cBMI in patients with alcoholic hepatitis. Underweight
cBMIb18.5 kg/m2, normal cBMI 18.5–24.9 kg/m2, overweight cBMI 25–29.9 kg/m2, obese
cBMI ≥ 30 kg/m2.
Fig. 2. A univariate analysis of survival after admission with alcoholic hepatitis by cBMI categor
account baseline factors C incidence of acute renal failure was greater in obese patients with A
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3 T3-derived adipocytes were used for in vitrowork to examine the
inﬂuence of alcohol on adipocytes. Brieﬂy, for adipocyte differentiation,
the 3 T3-derived adipocyteswere plated 1×105 cells/well. After conﬂu-
ence, cells were induced differentiationwith 10% FBS+5 μg/mL insulin,
0.5 mM IBMX, 1 μM Dex, T3 and Rosiglitazone. After 2 days, cells were
changed to amedium containing 10% FBS, insulin, T3 and Rosiglitazone.
After 4 days, cells were changed with the same medium again. Cells
were cultured to conﬂuence and then incubated with varying concen-
trations of alcohol: 0, 17.4 and 50mmol/L. The concentrations of alcohol
used in experiments were chosen to reﬂect serum concentrations of al-
cohol after binge drinking [17]: a blood alcohol concentration of
0.08 g/dL corresponds to 17.4 mmol/L. Concentrations much in excess
of this are lethal [18].
2.5. In vivo experiments of high-fat diet (HFD)-plus-binge ethanol feeding
To investigate the combination of obesity and alcohol on liver func-
tion, a model of HFD-plus-binge ethanol feeding was used as described
previously [19,20]. Brieﬂy, C57/B6micewere given a high fat diet (HFD,
60% of calories from fat, catalog no. D12492; Research Diets, NewBruns-
wick, NJ) for three months. Mice were divided into four groups of ﬁve
mice. In addition to HFD, groups received either single or multiple alco-
hol binges of alcohol or calorie-matched maltose via gavage. For singley log rank p b .001. B multivariate Cox proportional hazard analysis of survival taking into
H (Chi squared p = .032) D no difference in the incidence of infection was observed.
Table 2
serum proteome from patients with alcoholic hepatitis. All values are relative to patients
with a normal corrected BMI (18.5–24.9 kg/m2).
cBMI category
Underweight Normal Overweight Obese
FGF basic −8.3 0.0 −2.1 −22.0
BMP-4 −10.0 0.0 −13.7 −18.6
CXCL10 −4.1 0.0 −6.1 −16.9
CRP 2.9 0.0 −12.4 −14.5
Adiponectin −9.9 0.0 −9.0 −14.4
IL-11 −10.4 0.0 −14.8 −14.1
IL-10 −8.9 0.0 −15.5 −13.6
Pappalysin −2.1 0.0 −14.0 −13.3
IL-1B −10.3 0.0 −11.5 −12.0
Angiopoietin-like 2 −0.4 0.0 1.5 −11.4
LIF −8.2 0.0 −11.8 −11.2
VEGF −9.1 0.0 −11.0 −10.3
Angiopoietin-1 −2.4 0.0 0.5 −7.6
ICAM-1 −2.3 0.0 −12.1 −4.0
Dkk-1 6.7 0.0 −5.5 −3.8
IGFBP-3 11.9 0.0 −1.8 −3.1
CCL20 3.3 0.0 −0.6 −1.6
Complement factor D −6.5 0.0 −3.1 −1.2
TFF-3 8.2 0.0 3.7 −0.8
FGF-19 −15.2 0.0 1.9 −0.6
C5/C5a 10.3 0.0 −4.7 0.6
TNF-a −0.8 0.0 −2.4 1.0
Angiopoietin-1 7.8 0.0 5.9 1.2
Leptin −4.7 0.0 2.0 2.5
IL-32a 27.1 0.0 3.6 5.9
CCL2 11.3 0.0 5.7 6.8
IL18BPa 9.0 0.0 1.1 9.4
GRO-a 14.8 0.0 1.5 9.7
CCL2 18.0 0.0 2.9 11.3
CD30 6.2 0.0 −2.5 12.1
RBP4 9.7 0.0 1.4 12.5
Growth Hormone 7.3 0.0 −0.2 13.6
CD40 ligand 11.2 0.0 0.0 15.0
Leptin −2.4 0.0 6.7 15.1
uPAR 12.1 0.0 3.7 16.7
Flt-3 ligand 11.1 0.0 12.9 17.0
CCL17 22.4 0.0 21.4 20.7
Angiopoietin-2 12.5 0.0 11.9 21.4
FGF-19 12.6 0.0 19.6 26.4
CXCL11 8.7 0.0 14.6 40.1
514 R. Parker et al. / EBioMedicine 45 (2019) 511–518binge, mice were administered a single gavage of 5 g/kg ethanol. For
multiple binges, mice were administered 3 g/kg ethanol twice a week
for a total of 8 times during the ﬁnal month of HFD feeding. At the end
of the experiment mice underwent terminal anaesthesia 9 h after the
ﬁnal gavage. Blood for analysis of serum was obtained through cardiac
puncture. Liver and epididymal adipose tissue was harvested, snap fro-
zen in liquid nitrogen and stored at−80 °C until analysis.
2.5.1. Biochemical assays
The levels of serum alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), triglyceride (TG) and cholesterol (Chol)weremea-
suredwith IDEXXCatalystDx analyzer (IDEXXLaboratories,Westbrook,
Maine).
2.5.2. Real time-Polymerase chain reaction (PCR)
Total RNAwas isolated fromAT, liver and3 T3-derived adipocytes by
using Trizol Reagent (Invitrogen). cDNAwas synthesized by using cDNA
RT kit (Applied Biosystems, Forster City, CA). The expression levels of
genes were measured with quantitative real-time PCR by using ABI
PRISM 7500 real-time PCR detection system (Applied Biosystems, Fos-
ter City, CA).
2.5.3. Oil-red-O staining
3 T3-derived adipocytes cellswereﬁxedwith 10% formaldehyde and
washed with 60% isopropanol. Oil-red-O (sigma cat. O-0625) solution
was added to the completed dried well and incubated at room temper-
ature for 10 min. The O.D values were measured at 520 nm in a
spectrophotometer.
2.6. Statistical analysis
Correlation between BMI and volume of adipose and muscle tissue
were examined by linear regression to calculate coefﬁcient of determi-
nation (r2) values. cBMI groups were compared with one-way analysis
of variance (ANOVA). Survival was analysed with univariate Kaplan
Meier analysis andmultivariate Cox proportional hazard analysis, to cal-
culate hazard ratios (HR). SPSS v23 (IBM, New York USA) was used for
statistical analyses.
3. Results
3.1. cBMI correlates with adiposity in AH
Body composition was analysed in a subgroup of 60 patients from
the entire cohort who underwent CT imaging during admission. This
allowed for accurate determination of the volume of ascites, subcutane-
ous and visceral adipose tissue and muscle volume. Analysis of body
composition showed that cBMI correlatedwith volume of subcutaneous
and to a lesser extent intra-abdominal adipose tissue (r2=0.62, p b .001
and r2 = 0.11 p= .024 respectively) (supplementary ﬁg. 2). cBMI did
not correlate with volume of muscle (r2 = 0.03, p= .215). Thus, cBMI
is a measure of adiposity in alcoholic hepatitis.
3.2. Prevalence and consequences of obesity
The total cohort of 233 patients were used to examine the effect of
obesity in AH. Characteristics of patients are shown in Table 1. cBMI
was used to classify patients as underweight, normal, overweight or
obese. Overweight and obesity were common amongst patients
with AH (29% and 19% respectively) (Fig. 1). Characteristics of each
cBMI category are shown in Table 1. Groups differed with respect to
serum sodium concentration (one-way ANOVA p b .001), severity of as-
cites (p= .002) and urea (p= .007). Univariate Kaplan-Meier analysis
showed that cBMI category was associated with 90-day survival (log
rank p= .005) (Fig. 2A).90-day mortality was worse in underweight patients (63%) and
obese patients (40%) compared to normal or overweight patients (90-
day mortality 34% and 24% respectively). These ﬁndings remained
when analysis was limited to patients without ascites to remove any
possibility of interference in assessment of adiposity by ascites (supple-
mentary ﬁg. 3). Multivariate analysis (to control for baseline differences
in the severity of ascites, serum urea and sodium concentration be-
tween cBMI groups) conﬁrmed that, compared to a normal cBMI, un-
derweight (HR 3.37, 95%CI 1.40–8.09, p= .007) and obesity (HR 2.81,
1.21–4.25, p= .022) were independently associated with mortality at
3 months after admission (Fig. 2B). Overweight was not associated
with mortality (HR 1.09, 0.52–2.29, p= .816) Obesity was also associ-
ated with greater incidence of renal failure (Chi-squared p = .032)
(Fig. 2C) but not infection (Fig. 2D).
3.3. Inﬂammatory and metabolic phenotyping
The serum inﬂammatory phenotype was markedly different in pa-
tients with AH and obesity compared to normal cBMI (Table 2, Fig. 3).
There was a clear continuum from overweight to obese in most of the
factors analysed, especially when the most up or down-regulated fac-
tors were considered (Fig. 4). Otherwise inﬂammatory and metabolic
pathways were remarkably similar between extremes of cBMI with
only a few pathways differing in proteomic analysis. Interestingly, al-
though leptin concentration was up-regulated to a greater extent in
obese patients as might be expected, adiponectin was relatively
Fig. 3. proteome analysis of inﬂammatory factors in serum from patients with AH and obesity. All changes are compared to patients with AH and normal cBMI (18.5–24.9 kg/m2).
515R. Parker et al. / EBioMedicine 45 (2019) 511–518decreased in both underweight and obese patients compared to normal
cBMI. The most striking difference was seen in CXCL11, which was
markedly up-regulated (40% greater) in obese patients compared to
the group with normal cBMI. To conﬁrm this result, single-target
ELISA was performed to which showed that serum CXCL11 concentra-
tion was correlated with cBMI in patients with AH (r2 0.35, p = .001)
(Fig. 5).
3.4. Ethanol induces CXCL11 gene expression in vivo and in vitro models of
ALD
A murine model of obesity and alcoholic hepatitis induced by high-
fat diet (HFD) feeding plus binge ethanol was used to investigate the
relative contributions of adipose and liver tissue to the inﬂammatory
changes observed in patients with AH. The experimental diets induced
liver injury, evidenced by increased circulating ALT and ASTFGF basic BMP-4 CXCL10 CRP Adiponectin
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Fig. 4. relative values of A the ﬁve most-downregulated factorconcentration and typical changes of steatohepatitis on histology (sup-
plementary ﬁg. 4). Consistent with previous results, HFD and binges of
alcohol caused greater liver injury compared to maltose fed mice evi-
denced by higher circulating transaminases, cholesterol and triglycer-
ides (Fig. 6A). The relative gene expression of targets identiﬁed in
analysis of human proteome was analysed. The combination of alcohol
and obesity altered gene expression with the most obvious change
being expression of CXCL11, which was markedly up-regulated in adi-
pose tissue without any signiﬁcant changes being seen in liver tissue
(two way ANOVA p= .008)(Fig. 6B).
To conﬁrm alcohol-mediated alterations in CXCL11 in adipose tissue,
3 T3-derived adipocyteswere incubatedwith alcohol for 7 days. CXCL11
gene expression was up-regulated, with most marked increase seen at
17.4 mmol/L of ethanol - a physiological dose (Fig. 6C). In parallel
with changes in gene expression, a reduction in the lipid content of 3
T3-derived adipocytes was observed when assessed by oil-red-OFlt-3 ligand CCL17 Angiopoietin-2 FGF-19 CXCL110
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s and B the ﬁve most-upregulated factors by cBMI group.
Fig. 5. analysis of CXCL11 concentration in serum from patients with AH. A CXCL11 signiﬁcantly overexpressed in obese AH, B serum CXCL11 correlates with cBMI.
516 R. Parker et al. / EBioMedicine 45 (2019) 511–518staining (Fig. 6D) consistent with increased lipotoxicity secondary to
impaired adipocyte lipid storage induced by alcohol.
4. Discussion
Previous epidemiological studies have observed synergy between
obesity and alcohol in terms of the risk of liver disease [6,7] and the
risk of liver-related death [8]. Clinical studies have conﬁrmed that adi-
pose tissue is inﬂamed in patientswith alcoholic liver disease and corre-
lateswith the severity of liver inﬂammation [11,21]. Our data add to this
knowledge by showing that in patientswith AH, the severe form of ALD,
obesity is a risk factor for short-termmorbidity and mortality. This is in
part driven by a greater incidence of renal failure. Patients with obesity
and AH have a different inﬂammatory phenotype where CXCL11 inFig. 6. C57/B6 mice were fed with a high fat diet for three months and received binge alcohol
increased by HFD and alcohol. B HFD and multiple alcohol binges caused differential changes
adipose tissue. 3 T3-derived adipocytes were incubated with ethanol. C Increased gene exp
adipocytes was reduced by ethanol in a dose-dependent manner illustrated with Oil-red O staparticular was seen in high concentrations. This inﬂammatory pheno-
type is drivenby adipose tissue, as experimentswith isolated adipocytes
and in animalmodels of AH showed that induction of CXCL11 by alcohol
is speciﬁc to adipose tissue.
It is striking that whilst the inﬂammatory phenotype described in the
serumproteome showed a progression from overweight to obese (Fig. 4,
Fig. 5) this did not translate into a similar progression in clinical events,
where mortality and morbidity was markedly increased in obese pa-
tients and but not in overweight patients. Our data cannot provide and
explaination for this phenomenon. It could be speculated that the accu-
mulation of multiple dysregulated pathways leads to worse clinical out-
comes. Larger studies would be required to allow for robust mortality
analysis based on smaller ranges of cBMI to look for increasingmortality
with small increases in body mass. This is a limitation of these data.to induce liver injury. A circulating concentration of transaminases and triglycerides were
in gene expression in liver and adipose tissue. CXCL11 was predominantly increased in
ression of CXCL11 was seen at physiological doses at ethanol. D triglyceride loading of
ining.
517R. Parker et al. / EBioMedicine 45 (2019) 511–518This study is based on careful evaluation of the severity of ascites to
allow accurate assessment of BMI and body composition. Other systems
of correcting for the presence of ascites in the assessment of BMI are
used [22] but are not based on analysis of body composition. This meth-
odology allowed us to be conﬁdent that BMI was a surrogate marker of
overall adiposity. Conversely, this analysis also underpins previous
work that has shown that sarcopaenia cannot be adequately assessed
byBMI in patientswith liver disease [23]. In keepingwith other systems,
we categorised ascites into grades of severity based on US ﬁndings. This
categorisation may have introduced an element of inaccuracy to our
clinical ﬁndings as it relies on the judgment of clinicians, however our
results remained valid when we only considered patients without any
evidence of ascites where no correction to BMI was necessary.
The patients included in this study were diagnosed with AH on clin-
ical grounds; biopsy was not required for inclusion. Published data sug-
gest that clinical diagnoses of AH are accurate [24], especially when
patients have a marked hyperbilirubinaemia [25], which was clearly
the case in our cohort. This is reﬂected in the recent NIAAA statement
regarding theneed for biopsy in AH [13],where biopsy is only suggested
for cases of clinical uncertainty.
Obesity is increasingly common on a population level [26], where
hazardous drinking and early alcoholic liver disease are often associated
with obesity [6,27]. Although obesity may often fade or resolve in ad-
vanced cirrhosis as sarcopaenia develops, it is common to manage pa-
tients where both alcohol and the metabolic syndrome can both
contribute to the development of liver disease. Our data relate only to
adiposity andwe are unable to describe the role of other aspects ofmet-
abolic syndrome such as insulin resistance, hypertension or
dyslipidaemia but data in animals and other human liver disease, prin-
cipally NAFLD that suggest they are deleterious [28].
We observed a different inﬂammatory phenotype in obese AH pa-
tients verse non-obese AH patients. When we explored this further in
the laboratory we found that this was due in part to a contribution
from adipose tissue. In particular alcohol caused the expression of
CXCL11 expression to increase in adipose tissue but not in the liver.
CXCL11 is classically a T-lymphocyte chemoattractant via interaction
with CXCR3. Interestingly CXCL11 may be downregulated by
adiponectin. Adiponectin, an adipokine that reduces adipose inﬂamma-
tion and systemic insulin resistance, [29] is well recognised to be in-
creased by alcohol consumption [30,31] and is increased in ArLD [32]
[33]. This is in contrast to obesity where decreased concentrations of
adiponectin are observed [34]. The ﬁnding of increased CXCL11 in
obese AH suggests that there may be a failure of down-regulation of
CXCL11 by adiponectin, or that alcohol use in obesity may still be asso-
ciated with decreased adiponectin and consequent increased CXCL11
production. This was indeed the case in our cohort where the combina-
tion of AH and obesity was associated with a marked decrease in
adiponectin, compared to normal BMI (supplementary table 1).
The expression of CXCL11 in our murine model of alcohol and obe-
sity was investigated with analysis of gene expression in response to
high fat diet feeding, with or without administration of ethanol; how-
ever, the function of CXCL11 was unable to explored in C57BL/6 mice
due to a frame shift germline mutation of the Cxcl11 gene in C57BL/6
mice [35]. This mutation results in expression of a variant form of the
CXCL11 protein that is not functional [36]. Thus whilst the expression
of mRNA can be measured, seeking to antagonize the effect of CXCL11
cannot be performed in this standard model of obesity and alcohol
abuse.
Obesity exerts a deleterious effect in AH. Important differences are
seen in the clinical and inﬂammatory changes that occur, between
non-obese and obese patients. Our data highlight CXCL11 as one of
the pathways that differ. The interplay between alcohol, metabolic fac-
tors and hepatic inﬂammation is complex and is far from fully explored.
Careful further studies are required to understand this in more detail.
Given the prevalence of both alcohol abuse and themetabolic syndrome
these studies are urgently needed.Acknowledgements
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